2. Academic Validation
  3. N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections

N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections

  • Bioorg Med Chem Lett. 2013 Apr 1;23(7):2172-6. doi: 10.1016/j.bmcl.2013.01.108.
Yanming Du 1,  Hong Ye,  Tina Gill,  Lijuan Wang,  Fang Guo,  Andrea Cuconati,  Ju-Tao Guo,  Timothy M Block,  Jinhong Chang,  Xiaodong Xu
Affiliations

Affiliation

  • 1 Institute for Hepatitis and Virus Research, 3805 Old Easton Road, Doylestown, PA 18902, USA. yanming.du@ihvr.org
PMID: 23453839 DOI: 10.1016/j.bmcl.2013.01.108
Abstract

Novel N-alkyldeoxynojirimycins (NADNJs) with two hydrophobic groups attached to a nitrogen linker on the alkyl chain were designed. A novel NADNJ containing a terminal tertiary carboxamide moiety was discovered that was a potent inhibitor against BVDV. Further optimization resulted in a structurally more stable lead compound 24 with a submicromolar EC50 against BVDV, Dengue, and Tacaribe; and low cytotoxicity.

Figures